The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Capecitabine Market Research Report 2024
Synopsis
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
The global Capecitabine market was valued at US$ 1026.2 million in 2023 and is anticipated to reach US$ 997.5 million by 2030, witnessing a CAGR of -0.4% during the forecast period 2024-2030.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
This report aims to provide a comprehensive presentation of the global market for Capecitabine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Capecitabine.
Report Scope
The Capecitabine market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Capecitabine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Capecitabine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Segment by Type
500 mg
150 mg
Segment by Application
Breast Cancer
Colorectal Cancer
Stomach Cancer
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Capecitabine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Capecitabine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
The global Capecitabine market was valued at US$ 1026.2 million in 2023 and is anticipated to reach US$ 997.5 million by 2030, witnessing a CAGR of -0.4% during the forecast period 2024-2030.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
This report aims to provide a comprehensive presentation of the global market for Capecitabine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Capecitabine.
Report Scope
The Capecitabine market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Capecitabine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Capecitabine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Segment by Type
500 mg
150 mg
Segment by Application
Breast Cancer
Colorectal Cancer
Stomach Cancer
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Capecitabine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Capecitabine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Capecitabine Market Overview
1.1 Product Overview and Scope of Capecitabine
1.2 Capecitabine Segment by Type
1.2.1 Global Capecitabine Market Value Comparison by Type (2024-2030)
1.2.2 500 mg
1.2.3 150 mg
1.3 Capecitabine Segment by Application
1.3.1 Global Capecitabine Market Value by Application: (2024-2030)
1.3.2 Breast Cancer
1.3.3 Colorectal Cancer
1.3.4 Stomach Cancer
1.4 Global Capecitabine Market Size Estimates and Forecasts
1.4.1 Global Capecitabine Revenue 2019-2030
1.4.2 Global Capecitabine Sales 2019-2030
1.4.3 Global Capecitabine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Capecitabine Market Competition by Manufacturers
2.1 Global Capecitabine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Capecitabine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Capecitabine Average Price by Manufacturers (2019-2024)
2.4 Global Capecitabine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Capecitabine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Capecitabine, Product Type & Application
2.7 Capecitabine Market Competitive Situation and Trends
2.7.1 Capecitabine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Capecitabine Players Market Share by Revenue
2.7.3 Global Capecitabine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Capecitabine Retrospective Market Scenario by Region
3.1 Global Capecitabine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Capecitabine Global Capecitabine Sales by Region: 2019-2030
3.2.1 Global Capecitabine Sales by Region: 2019-2024
3.2.2 Global Capecitabine Sales by Region: 2025-2030
3.3 Global Capecitabine Global Capecitabine Revenue by Region: 2019-2030
3.3.1 Global Capecitabine Revenue by Region: 2019-2024
3.3.2 Global Capecitabine Revenue by Region: 2025-2030
3.4 North America Capecitabine Market Facts & Figures by Country
3.4.1 North America Capecitabine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Capecitabine Sales by Country (2019-2030)
3.4.3 North America Capecitabine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Capecitabine Market Facts & Figures by Country
3.5.1 Europe Capecitabine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Capecitabine Sales by Country (2019-2030)
3.5.3 Europe Capecitabine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Capecitabine Market Facts & Figures by Country
3.6.1 Asia Pacific Capecitabine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Capecitabine Sales by Country (2019-2030)
3.6.3 Asia Pacific Capecitabine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Capecitabine Market Facts & Figures by Country
3.7.1 Latin America Capecitabine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Capecitabine Sales by Country (2019-2030)
3.7.3 Latin America Capecitabine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Capecitabine Market Facts & Figures by Country
3.8.1 Middle East and Africa Capecitabine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Capecitabine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Capecitabine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Capecitabine Sales by Type (2019-2030)
4.1.1 Global Capecitabine Sales by Type (2019-2024)
4.1.2 Global Capecitabine Sales by Type (2025-2030)
4.1.3 Global Capecitabine Sales Market Share by Type (2019-2030)
4.2 Global Capecitabine Revenue by Type (2019-2030)
4.2.1 Global Capecitabine Revenue by Type (2019-2024)
4.2.2 Global Capecitabine Revenue by Type (2025-2030)
4.2.3 Global Capecitabine Revenue Market Share by Type (2019-2030)
4.3 Global Capecitabine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Capecitabine Sales by Application (2019-2030)
5.1.1 Global Capecitabine Sales by Application (2019-2024)
5.1.2 Global Capecitabine Sales by Application (2025-2030)
5.1.3 Global Capecitabine Sales Market Share by Application (2019-2030)
5.2 Global Capecitabine Revenue by Application (2019-2030)
5.2.1 Global Capecitabine Revenue by Application (2019-2024)
5.2.2 Global Capecitabine Revenue by Application (2025-2030)
5.2.3 Global Capecitabine Revenue Market Share by Application (2019-2030)
5.3 Global Capecitabine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Capecitabine Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Teva Capecitabine Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Corporation Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Capecitabine Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 Hikma
6.4.1 Hikma Corporation Information
6.4.2 Hikma Description and Business Overview
6.4.3 Hikma Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hikma Capecitabine Product Portfolio
6.4.5 Hikma Recent Developments/Updates
6.5 Hengrui Medicine
6.5.1 Hengrui Medicine Corporation Information
6.5.2 Hengrui Medicine Description and Business Overview
6.5.3 Hengrui Medicine Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hengrui Medicine Capecitabine Product Portfolio
6.5.5 Hengrui Medicine Recent Developments/Updates
6.6 Cipla
6.6.1 Cipla Corporation Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Cipla Capecitabine Product Portfolio
6.6.5 Cipla Recent Developments/Updates
6.7 Reliance Group
6.6.1 Reliance Group Corporation Information
6.6.2 Reliance Group Description and Business Overview
6.6.3 Reliance Group Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Reliance Group Capecitabine Product Portfolio
6.7.5 Reliance Group Recent Developments/Updates
6.8 Hetero
6.8.1 Hetero Corporation Information
6.8.2 Hetero Description and Business Overview
6.8.3 Hetero Capecitabine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hetero Capecitabine Product Portfolio
6.8.5 Hetero Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Capecitabine Industry Chain Analysis
7.2 Capecitabine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Capecitabine Production Mode & Process
7.4 Capecitabine Sales and Marketing
7.4.1 Capecitabine Sales Channels
7.4.2 Capecitabine Distributors
7.5 Capecitabine Customers
8 Capecitabine Market Dynamics
8.1 Capecitabine Industry Trends
8.2 Capecitabine Market Drivers
8.3 Capecitabine Market Challenges
8.4 Capecitabine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
